Serrapeptase 120,000 SU
Natural health product licensed in Canada
- Licence holder
- Biomed International Products Corp.
- NPN or DIN-HM
- 80084599
- Status
- Active licence
- Licence date
- 19 April 2018
- Revision date
- 15 May 2024
- Form
- Capsule, libération-retardée
- Route of administration
- Orale
- Application type
- Officinale
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
Medicinal composition not provided.
Non-medicinal ingredients
Cellulose microcristalline, Maltodextrine, Dextrine, Copolymère d'acide méthacrylique, Hydroxypropylméthylcellulose
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | minimum: 19 years | 1 Capsule | 1 Tous les jours |
Uses authorised in Canada
Proteolytic Enzyme. Helps to reduce symptoms such as pain, quantity of secretion, inability to perceive smell and stuffy nose from ear, nose and/or throat infections. Mucolytic enzyme that helps break down mucous. Helps reduce and/or relieve postoperative cheek swelling and/or pain after dental surgery.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Précautions et mises en garde
If symptoms persist or worsen, discontinue use and consult a health care practitioner. If you are pregnant or breastfeeding, consult a health care practitioner prior to use. If you have a gastrointestinal lesion/ulcer, are taking anticoagulant/blood thinner or anti-inflammatory medication, or are having surgery, consult a health care practitioner prior to use.
- Effets indésirables connus
Hypersensitivity/allergy has been known to occur; in which case, discontinue use.
Source
Official Health Canada record, licence 80084599
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).
List recorded in 2024. Photograph the packaging to check whether it has changed. Photograph the packaging